141 related articles for article (PubMed ID: 38102271)
1. Complement C3 as a drug target in periodontitis.
Wadia R
Br Dent J; 2023 Dec; 235(12):965. PubMed ID: 38102271
[No Abstract] [Full Text] [Related]
2. Complement C3 as a potential drug target in periodontitis: Evidence from the cis-Mendelian randomization approach.
Alayash Z; Baumeister SE; Holtfreter B; Kocher T; Baurecht H; Ehmke B; Nolde M; Reckelkamm SL
J Clin Periodontol; 2024 Feb; 51(2):127-134. PubMed ID: 37926509
[TBL] [Abstract][Full Text] [Related]
3. Gingival Exudatome Dynamics Implicate Inhibition of the Alternative Complement Pathway in the Protective Action of the C3 Inhibitor Cp40 in Nonhuman Primate Periodontitis.
Bostanci N; Bao K; Li X; Maekawa T; Grossmann J; Panse C; Briones RA; Resuello RRG; Tuplano JV; Garcia CAG; Reis ES; Lambris JD; Hajishengallis G
J Proteome Res; 2018 Sep; 17(9):3153-3175. PubMed ID: 30111112
[TBL] [Abstract][Full Text] [Related]
4. Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis.
Maekawa T; Abe T; Hajishengallis E; Hosur KB; DeAngelis RA; Ricklin D; Lambris JD; Hajishengallis G
J Immunol; 2014 Jun; 192(12):6020-7. PubMed ID: 24808362
[TBL] [Abstract][Full Text] [Related]
5. Complement therapeutics in inflammatory diseases: promising drug candidates for C3-targeted intervention.
Mastellos DC; Ricklin D; Hajishengallis E; Hajishengallis G; Lambris JD
Mol Oral Microbiol; 2016 Feb; 31(1):3-17. PubMed ID: 26332138
[TBL] [Abstract][Full Text] [Related]
6. C3-targeted therapy in periodontal disease: moving closer to the clinic.
Hajishengallis G; Hasturk H; Lambris JD;
Trends Immunol; 2021 Oct; 42(10):856-864. PubMed ID: 34483038
[TBL] [Abstract][Full Text] [Related]
7. Immunology of chronic generalized periodontitis. 2. Estimation of total hemolytic complement (CH 50) and its fractions C3 and C4.
Anil S; Beena VT; Remani P; Haseenabeevi M; Vijayakumar T
Indian J Dent Res; 1991; 2(3-4):35-9. PubMed ID: 1821159
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of pre-existing natural periodontitis in non-human primates by a locally administered peptide inhibitor of complement C3.
Maekawa T; Briones RA; Resuello RR; Tuplano JV; Hajishengallis E; Kajikawa T; Koutsogiannaki S; Garcia CA; Ricklin D; Lambris JD; Hajishengallis G
J Clin Periodontol; 2016 Mar; 43(3):238-49. PubMed ID: 26728318
[TBL] [Abstract][Full Text] [Related]
9. Total hemolytic complement (CH50) and its fractions (C3 and C4) in the sera of diabetic patients with periodontitis.
Anil S; Remani P; Vijayakumar T; Joseph PA
J Periodontol; 1990 Jan; 61(1):27-9. PubMed ID: 2107297
[TBL] [Abstract][Full Text] [Related]
10. Complement inhibition in pre-clinical models of periodontitis and prospects for clinical application.
Hajishengallis G; Hajishengallis E; Kajikawa T; Wang B; Yancopoulou D; Ricklin D; Lambris JD
Semin Immunol; 2016 Jun; 28(3):285-91. PubMed ID: 27021500
[TBL] [Abstract][Full Text] [Related]
11. Phase IIa clinical trial of complement C3 inhibitor AMY-101 in adults with periodontal inflammation.
Hasturk H; Hajishengallis G; ; Lambris JD; Mastellos DC; Yancopoulou D
J Clin Invest; 2021 Dec; 131(23):. PubMed ID: 34618684
[TBL] [Abstract][Full Text] [Related]
12. Complement-Dependent Mechanisms and Interventions in Periodontal Disease.
Hajishengallis G; Kajikawa T; Hajishengallis E; Maekawa T; Reis ES; Mastellos DC; Yancopoulou D; Hasturk H; Lambris JD
Front Immunol; 2019; 10():406. PubMed ID: 30915073
[TBL] [Abstract][Full Text] [Related]
13. Total hemolytic complement (CH50) and its fractions C3 and C4 in the sera of patients with localized juvenile periodontitis.
Anil S; Beena VT; Remani P; Mysore J; Vijayakumar T
Ann Dent; 1993; 52(1):18-20. PubMed ID: 8323245
[TBL] [Abstract][Full Text] [Related]
14. Complement 3 mediates periodontal destruction in patients with type 2 diabetes by regulating macrophage polarization in periodontal tissues.
Li Y; Wang X; Wang S; Zhu C; Guo J; Li K; Li A
Cell Prolif; 2020 Oct; 53(10):e12886. PubMed ID: 32794619
[TBL] [Abstract][Full Text] [Related]
15. Immunoglobulins and complement in human periodontitis.
Toto PD; Lin LM; Gargiulo AW
J Periodontol; 1978 Dec; 49(12):631-4. PubMed ID: 366101
[TBL] [Abstract][Full Text] [Related]
16. C3-targeted host-modulation approaches to oral inflammatory conditions.
Kajikawa T; Mastellos DC; Hasturk H; Kotsakis GA; Yancopoulou D; Lambris JD; Hajishengallis G
Semin Immunol; 2022 Jan; 59():101608. PubMed ID: 35691883
[TBL] [Abstract][Full Text] [Related]
17. Complement Is Required for Microbe-Driven Induction of Th17 and Periodontitis.
Wang H; Ideguchi H; Kajikawa T; Mastellos DC; Lambris JD; Hajishengallis G
J Immunol; 2022 Oct; 209(7):1370-1378. PubMed ID: 36028293
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of C3 and IgG proteolysis enhances phagocytosis of Porphyromonas gingivalis.
Cutler CW; Arnold RR; Schenkein HA
J Immunol; 1993 Dec; 151(12):7016-29. PubMed ID: 8258706
[TBL] [Abstract][Full Text] [Related]
19. Pemphigus vulgaris with significant periodontal findings: a case report.
Pradeep AR; Manojkumar ST; Arjun R
J Calif Dent Assoc; 2010 May; 38(5):343-6. PubMed ID: 20572529
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous assessment of complement components C3, C4, and B and their cleavage products in human gingival fluid. I. Reliability of the method.
Niekrash CE; Patters MR
J Periodontal Res; 1985 May; 20(3):260-7. PubMed ID: 3160841
[No Abstract] [Full Text] [Related]
[Next] [New Search]
